Alport syndrome is a rare genetic kidney disorder that gradually affects the kidneys’ ability to work properly, and in many cases also impacts hearing and vision. Treatment focuses on slowing the progression of kidney damage and managing symptoms to help patients maintain their natural kidneys for as long as possible, improve their quality of life, and delay the need for dialysis or transplant.

Managing a Rare Genetic Kidney Condition

Alport syndrome presents unique challenges because it affects each person differently, depending on the type of genetic mutation involved and individual health factors. The condition arises from defects in type IV collagen, a structural protein essential for the filtering membranes in the kidneys, as well as structures in the ears and eyes. When these membranes don’t function properly, blood and protein can leak into the urine, and kidney function gradually declines over time.^[1]

The main goal of treating Alport syndrome is to preserve kidney function for as long as possible while addressing associated problems like high blood pressure, hearing loss, and vision changes. Unlike some diseases where treatments can reverse damage, current approaches to Alport syndrome focus on slowing progression and preventing complications. This means that early diagnosis and prompt treatment are particularly important for improving long-term outcomes.^[2]

Treatment strategies differ based on the stage of kidney disease, the person’s age, the presence of symptoms like protein in the urine (called proteinuria), and whether the patient has high blood pressure or other health concerns. Medical societies have developed clinical guidelines to help doctors provide the best care, though these recommendations continue to evolve as researchers learn more about the disease. At the same time, scientists are actively investigating new therapies through clinical trials, searching for more effective treatments and potentially even a cure.^[7]

Standard Treatment Approaches

The cornerstone of standard treatment for Alport syndrome involves medications that block the renin-angiotensin-aldosterone system (RAAS), a hormone system that regulates blood pressure and fluid balance in the body. These medications include two main classes: ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin receptor blockers). Common ACE inhibitors used for Alport syndrome include lisinopril and ramipril, while losartan is a frequently prescribed ARB.^[7]

What makes these medications valuable is that they are often prescribed even when a patient doesn’t have high blood pressure. Their benefit comes from reducing the amount of protein that leaks into the urine, which in turn slows the scarring process in the kidneys. By decreasing intraglomerular pressure—the pressure inside the tiny filtering units of the kidneys—these drugs reduce stress on the kidney structures. Additionally, by inhibiting angiotensin II, a substance that promotes scarring and damage in kidney tissue, ACE inhibitors and ARBs may help slow the progressive deterioration of kidney function.^[11]

A significant multicenter, randomized, placebo-controlled study examined the use of ramipril in children with Alport syndrome. The trial found that ramipril decreased the risk of disease progression by almost half compared to placebo. Importantly, no significant safety concerns emerged during the study, with adverse event rates being similar between the treatment and placebo groups. These findings support the practice of starting RAAS blockade early in childhood or adolescence when appropriate.^[11]

The duration of therapy with ACE inhibitors or ARBs is typically lifelong, as these medications need to be taken continuously to maintain their protective effects on the kidneys. Regular monitoring through blood tests and urine tests is necessary to check kidney function, measure protein levels in the urine, and watch for any side effects. Patients usually see a nephrologist—a doctor specializing in kidney diseases—for routine examinations so that complications like high blood pressure can be identified early and treated promptly.^[7]

Some patients may develop what is known as “aldosterone breakthrough,” where the body’s aldosterone levels rise again despite treatment with ACE inhibitors or ARBs. In these cases, doctors may consider adding mineralocorticoid receptor blockers, another class of medications that can help control blood pressure and reduce protein in the urine.^[10]

In addition to blood pressure medications, a small research study explored the benefits of combination therapy using multiple drugs together. This approach included an ACE inhibitor, an ARB, a non-dihydropyridine calcium channel blocker (such as diltiazem), and a statin (such as fluvastatin). In the nine adults with Alport syndrome who participated in the study, this combination safely reduced protein in the urine, controlled blood pressure and cholesterol levels, and appeared to halt disease progression in those who didn’t yet have significant kidney impairment. However, this was a small, short-term study, and more research is needed to confirm these findings.^[11]

Side effects from ACE inhibitors and ARBs are generally mild but can include dizziness, fatigue, a dry cough (more common with ACE inhibitors), or changes in kidney function tests. Patients should never stop taking these medications suddenly without consulting their doctor, as this could allow kidney damage to progress more rapidly. Women of childbearing age should discuss pregnancy plans with their healthcare team, as these medications are not safe to take during pregnancy and alternatives must be arranged.^[11]

Additional Standard Care Measures

Beyond specific kidney-protective medications, standard care for Alport syndrome includes managing complications as kidney disease advances. This might involve treating anemia with medications like erythropoietin, which stimulates red blood cell production, or using phosphate binders to control mineral imbalances that occur when kidneys don’t filter properly. If kidney disease progresses to end-stage kidney disease (ESKD), patients will need kidney replacement therapy, which can take the form of dialysis or kidney transplant.^[11]

Some reports suggest that treating bacterial infections promptly, using vitamin D analogs like paricalcitol for patients with elevated parathyroid hormone levels, and prescribing statins for those with abnormal cholesterol levels might also help slow disease progression and reduce the risk of cardiovascular problems. However, more research is needed to fully understand the benefits of these additional treatments in Alport syndrome specifically.^[11]

Hearing loss, which affects many people with Alport syndrome, typically develops progressively as kidney disease advances. The hearing loss is sensorineural, meaning it results from damage to the inner ear structures. While it rarely progresses to complete deafness, patients may benefit from hearing aids to maintain good communication and quality of life. Regular hearing evaluations are an important part of comprehensive care.^[5]

Eye abnormalities in Alport syndrome can include anterior lenticonus (cone-shaped lens), retinal flecks, and other changes. Although these rarely threaten vision, regular eye examinations allow doctors to monitor for any problems. In cases where the lens shape causes significant vision problems, lens replacement surgery similar to cataract surgery may be recommended.^[5]

Promising Therapies in Clinical Trials

While no treatment specifically approved by regulatory agencies for Alport syndrome exists yet, researchers are actively investigating several innovative approaches in clinical trials. These studies test whether new drugs or treatment strategies can be more effective than current standard care in slowing kidney disease progression or addressing the underlying genetic defect.^[10]

SGLT2 Inhibitors

A newer class of medications called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors) is showing promise for chronic kidney disease generally and is beginning to be studied in Alport syndrome. These drugs, which include medications like dapagliflozin (brand name Farxiga), were originally developed for diabetes but have demonstrated kidney-protective effects even in people without diabetes. They work by blocking the reabsorption of glucose and sodium in the kidney tubules, which reduces the workload on the kidneys and may slow disease progression.^[7]

The DAPA-CKD trial, a large study examining dapagliflozin in chronic kidney disease patients, suggested beneficial effects on kidney outcomes. Based on these promising results, adult Alport syndrome patients are increasingly being prescribed SGLT2 inhibitors in addition to ACE inhibitors or ARBs, though this use is still being studied specifically in Alport syndrome. A published case series reported benefits in Alport syndrome patients treated with SGLT2 inhibitors, and animal studies have shown that adding an SGLT2 inhibitor to ramipril improved kidney outcomes. The combination of ramipril, an SGLT2 inhibitor, and the mineralocorticoid receptor antagonist finerenone provided even more substantial improvements in animal models.^[10]

Gene Therapy and Molecular Approaches

Because Alport syndrome results from genetic mutations in the COL4A3, COL4A4, or COL4A5 genes, researchers are exploring whether gene therapy—introducing healthy copies of the defective gene—or gene editing—correcting the mutation directly—could provide a cure. While these approaches are not yet available as treatments, they represent active areas of investigation. The goal would be to restore the body’s ability to produce normal type IV collagen proteins, potentially halting or reversing kidney damage.^[7]

Other molecular approaches under investigation include anti-microRNA therapies, which work by blocking specific small RNA molecules that contribute to kidney scarring and damage. These experimental treatments aim to interrupt the disease process at a molecular level, potentially providing benefits beyond what current medications can achieve.^[11]

Other Investigational Drugs

Several other types of medications are being explored in research settings for Alport syndrome. Endothelin type A antagonists are drugs that block endothelin, a substance that can cause blood vessels to narrow and promote scarring in the kidneys. By blocking endothelin receptors, these medications might reduce kidney damage and slow disease progression.^[11]

Bardoxolone methyl is another experimental drug being investigated. This compound activates a cellular pathway that helps protect cells from oxidative stress and inflammation. In animal models and some early human studies in other kidney diseases, bardoxolone methyl has shown potential for preserving kidney function, though its specific effects in Alport syndrome are still being evaluated.^[11]

Researchers are also looking at modified versions of aminoglycosides—antibiotics that in their original form can damage kidneys—to see if altered versions might actually help treat Alport syndrome by allowing cells to “read through” certain types of genetic mutations. Lipid-modifying drugs beyond standard statins and hydroxychloroquine, a medication used for autoimmune conditions, are also under investigation for potential benefits in Alport syndrome.^[11]

Some studies have examined cyclosporine, an immunosuppressive medication, for Alport syndrome. A few reports suggested it might reduce protein in the urine and stabilize kidney function, but these studies were small and uncontrolled. Additionally, concerns exist that cyclosporine might accelerate scarring in the kidneys due to its own toxic effects on kidney tissue, so its use remains controversial and is not part of standard treatment recommendations.^[11]

Understanding Clinical Trial Phases

Clinical trials testing new treatments for Alport syndrome typically progress through several phases. Phase I trials primarily assess safety, determining appropriate dosing and looking for side effects in a small number of participants. Phase II trials examine whether the treatment appears effective while continuing to monitor safety, usually in a larger group of patients. Phase III trials compare the new treatment directly to standard care or placebo in large, randomized studies to definitively establish effectiveness and safety. Only after completing these phases and obtaining approval from regulatory agencies like the FDA can a treatment become part of standard medical practice.^[10]

Clinical trials for Alport syndrome are taking place in various locations around the world, including the United States, Europe, and other regions. Eligibility to participate depends on factors like age, disease stage, genetic type of Alport syndrome, kidney function level, and other health conditions. Patients interested in clinical trials should discuss options with their nephrologist and can also look for trial listings through patient organizations like the Alport Syndrome Foundation or clinical trial registries.^[7]

Most common treatment methods

• RAAS-blocking medications (ACE inhibitors and ARBs)
  • Lisinopril, ramipril, and losartan are commonly prescribed to reduce protein in urine and slow kidney damage
  • These medications work by decreasing pressure in the kidney filtering units and blocking substances that promote scarring
  • Often prescribed even when blood pressure is normal, as they protect kidney function
  • Lifelong treatment is typically needed, with regular monitoring through blood and urine tests
  • A major study showed ramipril reduced disease progression risk by nearly half in children with Alport syndrome
• SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors)
  • Medications like dapagliflozin (Farxiga) are increasingly used in addition to ACE inhibitors or ARBs in adults
  • Originally developed for diabetes but show kidney-protective effects in chronic kidney disease
  • Work by reducing glucose and sodium reabsorption, which decreases kidney workload
  • Animal studies showed improved outcomes when combined with ramipril and mineralocorticoid receptor antagonists
• Mineralocorticoid receptor blockers
  • May be added for patients who develop “aldosterone breakthrough” despite ACE inhibitor or ARB treatment
  • Help control blood pressure and reduce protein leakage into urine
  • Finerenone is one medication in this class being studied in combination with other treatments
• Combination therapy approaches
  • Some research has explored using ACE inhibitors, ARBs, calcium channel blockers like diltiazem, and statins like fluvastatin together
  • Small studies suggested this combination reduced protein in urine, controlled blood pressure and cholesterol, and halted progression in early disease
  • More research is needed to confirm these findings and establish this as standard practice
• Treatment of complications
  • Erythropoietin for anemia that develops as kidney function declines
  • Phosphate binders to control mineral imbalances when kidneys can’t filter properly
  • Prompt treatment of bacterial infections to help slow disease progression
  • Paricalcitol for adults with elevated parathyroid hormone levels
  • Statins for cholesterol abnormalities and cardiovascular protection
• Kidney replacement therapy
  • Dialysis or kidney transplant becomes necessary when kidney disease progresses to end-stage
  • Both hemodialysis and peritoneal dialysis are options depending on patient circumstances
  • Kidney transplant offers the possibility of restoring normal kidney function
• Management of hearing and vision problems
  • Hearing aids for progressive sensorineural hearing loss that affects many patients
  • Regular hearing evaluations to monitor changes over time
  • Regular eye examinations to detect and monitor eye abnormalities
  • Lens replacement surgery when cone-shaped lenses cause significant vision problems
• Investigational therapies in clinical trials
  • Gene therapy and gene editing approaches to correct the underlying genetic defect
  • Anti-microRNA therapies to block molecules that contribute to kidney scarring
  • Endothelin type A antagonists to reduce blood vessel constriction and kidney scarring
  • Bardoxolone methyl to protect cells from oxidative stress and inflammation
  • Modified aminoglycoside analogs designed to help cells read through certain genetic mutations
  • Hydroxychloroquine and other lipid-modifying drugs beyond standard statins